Welcome to our dedicated page for West Pharm Svcs SEC filings (Ticker: WST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
West Pharmaceutical Services, Inc. filings document the regulatory record of a Pennsylvania operating company that supplies injectable drug containment, delivery and contract-manufacturing services. Its Form 8-K reports commonly furnish quarterly and full-year operating results, financial presentation materials and Regulation FD disclosures tied to earnings releases.
West's proxy and annual meeting filings cover board elections, executive compensation, advisory votes and shareholder voting results for its common stock. Other current reports record executive-transition matters and related governance disclosures, while exhibit filings provide the formal press releases, presentations and Inline XBRL cover-page data attached to those events.
McMahon Robert W. reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services granted its SVP & Chief Financial Officer, Robert W. McMahon, two equity awards. He received 3,082 restricted stock units, each representing the right to one share of common stock, and options for 7,337 shares. Both awards vest in four equal annual installments beginning on March 1, 2027.
Poussot Rodolphe Jean reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services senior vice president of Strategy & Corporate Development Rodolphe Jean Poussot received equity awards on March 1, 2026. He was granted 437 restricted stock units, each representing one share of common stock, and stock options for 1,040 shares. Both awards vest in four equal annual installments beginning on March 1, 2027.
Winters Chad reported acquisition or exercise transactions in this Form 4 filing.
WEST PHARMACEUTICAL SERVICES INC executive Chad Winters, VP and Chief Accounting Officer, reported equity awards on restricted stock units and stock options. He received 340 restricted stock units and 808 stock options as grants, both described as derivative securities with no cash paid per unit in these awards.
Each restricted stock unit represents a contingent right to receive one share of WST common stock. Both the restricted stock units and the stock options vest in four equal annual installments beginning on March 1, 2027, creating a multi-year, performance- and service-linked compensation structure for this officer.
WEST PHARMACEUTICAL SERVICES INC senior vice president Rodolphe Jean Poussot reported equity compensation activity involving restricted stock units and common shares. On February 20, 2026, he exercised 383.382 restricted stock units, which converted into the same number of common shares at no cash cost.
Following this conversion, his directly held common stock position increased, then 129.545 shares of common stock were automatically withheld at $241.12 per share to cover tax obligations, leaving 561.235 common shares held directly after the transactions. Footnotes state that restricted stock units convert into common stock on a one-for-one basis and reference an earlier grant of 1,143 units vesting in three equal annual installments.
West Pharmaceutical Services VP & Treasurer Charles Witherspoon reported equity award activity involving restricted stock units and common shares. On February 20, 2026, 60.220 restricted stock units converted into 60.220 shares of common stock on a one-for-one basis, increasing his directly held common shares to 1,429.966.
To cover tax obligations related to the vesting, 22.069 common shares were disposed of at $241.12 per share through a tax-withholding transaction, leaving him with 1,407.897 directly owned common shares. After the transaction, he also directly held 177.644 restricted stock units, which can convert into common stock in the future under the award terms.
West Pharmaceutical Services VP and Chief Accounting Officer Chad Winters exercised restricted stock units into common stock and had shares withheld to cover taxes. On February 20, 2026, he converted 89.328 restricted stock units into the same number of common shares at $0.00 per share, increasing his direct common stock holdings to 1,552.994 shares. On the same date, 30.184 common shares were disposed of at $241.12 per share in a tax-withholding transaction, leaving him with 1,522.810 common shares directly owned. Footnotes state these restricted stock units convert to common stock on a one-for-one basis and relate to a prior grant that vests in four equal annual installments.
West Pharmaceutical Services senior vice president Rodolphe Jean Poussot reported equity compensation activity involving restricted stock units and common shares. He acquired 82.299 common shares through the exercise or conversion of restricted stock units, which convert into common stock on a one-for-one basis.
Following this conversion, 27.809 common shares were disposed of at 248.26 per share to cover tax obligations through a tax-withholding disposition, rather than an open-market sale. After these transactions, his direct common stock holdings totaled 307.398 shares, and he held 247.899 restricted stock units directly. A prior grant of 329 restricted stock units vests in four equal annual installments, including dividend equivalents.
West Pharmaceutical Services VP & Treasurer Charles Witherspoon reported two stock transactions in company common stock. He acquired 115.910 shares at a stated price of $0.0000, representing shares issued from performance stock units that vested for the 2023–2025 performance period.
On the same date, 41.519 shares were disposed of at $243.1900 per share to cover tax obligations through share withholding, rather than an open-market sale. After these transactions, he directly owned 1,369.746 shares of West Pharmaceutical Services common stock.
West Pharmaceutical Services VP and Chief Accounting Officer Chad Winters reported equity-related transactions involving company common stock. On February 17, 2026, he acquired 149.684 shares at a price of $0.00 per share as a grant or award. A footnote explains these shares resulted from performance stock units for the 2023–2025 performance period that vested and became payable on that date.
On the same date, Winters disposed of 50.579 shares at $243.19 per share to cover tax liabilities through share withholding, rather than an open-market sale. After these transactions, he directly owned 1,462.103 common shares.
West Pharmaceutical Services President and CEO Eric Mark Green reported several equity-related transactions. On February 17, 2026, he acquired 4,418.771 shares of common stock as a grant. On February 18, 2026, 1,318.810 restricted stock units, stemming from 2023–2025 performance stock units, converted into common stock on a one-for-one basis. To cover tax obligations, he disposed of 1,305.382 shares at $243.19 and 573.551 shares at $248.26. Following these transactions, he directly owned 175,160.6588 common shares and indirectly held 257.375 shares through a Non-Qualified Deferred Compensation Plan.